FDA — authorised 26 January 2001
- Application: NDA021227
- Marketing authorisation holder: MERCK
- Indication: Type 1 - New Molecular Entity
- Status: approved
🇺🇸 Cancidas in United States
FDA authorised Cancidas on 26 January 2001
Marketing authorisations
FDA — authorised 30 December 2016
- Application: NDA206110
- Marketing authorisation holder: FRESENIUS KABI USA
- Indication: Type 5 - New Formulation or New Manufacturer
- Status: approved
FDA — authorised 29 September 2017
- Application: ANDA207092
- Marketing authorisation holder: GLAND
- Status: approved
FDA — authorised 2 August 2019
- Application: ANDA200833
- Marketing authorisation holder: HENGRUI PHARMA
- Indication: Labeling
- Status: approved
FDA — authorised 18 July 2025
- Application: ANDA216506
- Marketing authorisation holder: HANGZHOU ZHONGMEI
- Status: approved
Cancidas in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in United States
Frequently asked questions
Is Cancidas approved in United States?
Yes. FDA authorised it on 26 January 2001; FDA authorised it on 30 December 2016; FDA authorised it on 29 September 2017.
Who is the marketing authorisation holder for Cancidas in United States?
MERCK holds the US marketing authorisation.